Fisher Center Discovery Program
To develop excellence in clinical research regarding environmental infectious pathogens, the Center has created the Fisher Center Discovery Program (FCDP). Goals of the FCDP include:
- Funding of grants for clinical research related to environmental infectious diseases
- Provision of resources for studies that lack traditional funding mechanisms
- Promotion of cross-disciplinary collaborative research
- Provision of mentoring opportunities for early career investigators
We award a maximum of $60,000 to individual Johns Hopkins researchers during a single annual grant cycle. Notifications about the grants opportunity are distributed by email via individual schools of the Johns Hopkins University and pertinent faculty list serves. All full-time faculty members of the Johns Hopkins University, especially junior faculty, are encouraged to apply. For questions concerning the grants program, please email firstname.lastname@example.org or call 443-287-4800.
These Discovery Program grants are possible through the generous support of Sherrilyn Fisher.
2022 Fisher Center Discovery Program Grant Cycle - Round 2
Important Changes for the 2022 Grant Cycle – Round 2
The FCDP will continue its focus on environmental infectious diseases. However, in response to the COVID-19 pandemic, we also offer the funding opportunity for clinical and translational research related to COVID-19 and SARS-CoV-2. Submissions with both a COVID-19/SARS-CoV-2 and environmental focus (e.g., built environments, environmental transmission) will receive special funding consideration. Basic laboratory research proposals will not be reviewed. Laboratory-based research will only be considered if it relates directly to clinical or translational research.
If you have questions regarding whether a COVID-19/SARS-CoV-2 and environmental infectious diseases proposal would be appropriate for the Fisher Center Discovery Program, please submit a Letter of Intent (form below)
Applicants are strongly encouraged to review the document FCDP Application Guidelines 2022 – Round 2 before completion of the proposal and application.
Letter of Intent submission deadline Monday, November 29, 2021. Form provided below.
Full Application submission deadline Wednesday, January 5, 2022 at 11:59 PM. Form provided below.
Award notice on or before January 31, 2022.
- On or before January 5, 2022 submit these documents via email, email@example.com.
- Save all documents as individual documents. Do not combine documents.
- The complete application package is composed of the following documents.
Documents to submit in the application package:
- FCDP Application Form 2022 – Round 2, provided below
- Protocol: abstract; background; objectives; methods; timeline; proposal benefits; endnotes
- Biosketch, Curriculum Vitae, or résumé of 1) The PI 2) Co-investigators 3) Staff receiving salary support, saved as individual files
- Letter of support from the Faculty preceptor for applicants who are not JHU faculty
- Letters of support from collaborators and research partners (optional, but encouraged), saved as individual files
- Budget – use template provided below
- Written justification of salary requests exceeding 50% of the monetary award, if necessary
- Written justification of laboratory supplies, equipment, and service requests exceeding 50% of the monetary award, if necessary
2022 Document Library
FCDP Request for Application 2022 – Round 2
FCDP Application Guidelines 2022 – Round 2
FCDP Frequently Asked Questions 2022 – Round 2
FCDP Letter of Intent Form 2022 – Round 2
FCDP Application 2022 – Round 2
FCDP Budget Template 2022
FCDP Prior Awarded Projects
Principal Investigators were Johns Hopkins University faculty at the time of award. Co-investigators are not listed.
|Year||Principal Investigator||Project Title|
|2021||Netz Arroyo, PhD||Point-of-need platform for population-scale monitoring of SARS-CoV-2 neutralizing antibodies|
|2021||Challice Bonifant, MD PhD||H84T-BanLec CAR-NK Cells as Treatment for SARS-CoV-2 Infection|
|2021||Karen Carroll, MD||Next Generation Sequencing for Pathogen Identification in Lower Respiratory Infections|
|2021||Meghan Frost Davis, DVM, MPH PhD||Immunologic markers associated with environmental exposure to enterotoxin-producing Staphylococcus aureus|
|2021||Maged Mohamed Harraz, MBBCh, MSc, PhD||Autophagic degradation of ACE2 as a Therapeutic Target in Covid-19|
|2021||Nitipong “Nate” Permapalung, MD, MPH||Optimizing Diagnostics for Environmentally Acquired Fungal Pneumonia Complicating COVID-19|
|2021||Matthew Robinson, MD||A comprehensive suite of web tools to predict COVID-19 trajectory|
|2021||Maxim Rosario, D.Phil., MB BCH BAO, MSc PhD||Adoptive NK cell Therapy for Acquired Fungal Infection|
|2020||Keira Cohen, MD||Early bactericidal activity of standard drugs used to treat Mycobacterium avium complex: a pilot study|
|2020||Gyanu Lamichhane, PhD||Developing antibiotic regimen to treat M. abscessus disease based on whole genome mining|
|2020||Michael Melia, MD||Beta-d-glucan and galactomannan curriculum|
|2020||Heba Mostafa, MD, PhD||Genomic Surveillance of Enteroviruses' Polymorphic Events that Correlate with Disease Severity and Neuro-virulence|
|2020||David Sullivan, MD||Murine Babesia Combination Chemotherapy|
|2020||Sean Zhang, MD, PhD||POC.auris: A 15-minute point-of-care detection of multi-drug resistant Candida auris|
|2018||Anthony K. L. Leung, PhD||Understanding how virus virulence is regulated by the ADP-ribosylhydrolase activity of the macrodomain - a potential drug target|
|2018||Kimberly M. Davis, PhD||The role of amoebae in enhancing the virulence of environmental human pathogens|
|2018||Brian Garibaldi, MD||Environmental transmission and traceability of aerosolized bio-stimulants in a clinical biocontainment unit|
|2017||Keeve Nachman, PhD||Building a baseline for assessing the human health impact of a landmark legislative intervention on antibiotic use in industrial poultry production|
|2017||Sabra L. Klein, PhD||Identification of early detection biomarkers and candidate therapeutics for congenital Zika virus infection|
|2017||Evan Bloch, MBChB, MD, MS||African BAOBAB (Babesia Observational Antibody) Study|
|2017||Aaron Milstone, MD||Impact of Heterogeneous Resistance Mechanisms on Hospital Transmission of Carbapenem-Resistant Enterobacteriaceae (CRE)|
|2016||Petros Karakousis, MD||Identifying molecular targets for preventing multidrug tolerance in Mycobacterium avium infection|
|2016||Diane Griffin, MD, PhD||The role of nsP3 in neurovirulence of chikungunya virus|
|2016||Patricia Simner, MSc, PhD||Molecular Epidemiology of Carbapenem Resistant Gram-Negative Organisms (CROs) at Johns Hopkins Hospital: Do Patients Infected with CROs Contaminate the Hospital Room Environment?|
|2016||Brian Schwartz, MD, MS||High-density poultry operations and associated infectious disease risks|
|2015||Kieren Marr, MD||Diagnostics for latent histoplasmosis|
|2015||Trish Perl, MD At UT SW since 2016.||The Home Environment: Infections among Patients Discharged Home with Venous Catheters|
|2015||Margaret Kosek, MD. At UVA since 2019.||Salivary diagnostics for pathogens of clinical significance in childhood environmental enteropathy|
|2014||Pranita Tamma, MD, MHS||An evidence-based screening approach to identify children at high risk for harboring multi-drug resistant Gram-negative organisms in the PICU|
|2014||Elizabeth Matsui, MD, MHS At UT Austin since 2018.||Home Environmental Exposure to Staphylococcal Bacteria and Asthma Exacerbation|
|2014||Christine Marie George, PhD||Identifying Environmental Transmission Routes for Shigellosis in Rural Settings using Pulsed-field Gel Electrophoresis|
|2014||Mark Soloski, PhD||Immune Events in Human Lyme Disease|
|2014||Nicole Parrish, PhD||Characterization of β-lactam Resistance in Enterobacteriaceae Isolated from the Chesapeake Bay and Upper Watershed|
|2014||Priya Duggal, PhD, MPH||Host Genetic Susceptibility to Cryptosporidia Infection|
|2013||Aaron Milstone, MD, MHS||Development and Clinical Evaluation of Laboratory Methods to Identify Reduced Antiseptic Susceptibility in Organisms Causing Healthcare Associated Infections|
|2013||Megan Reller, MD, MPH At Duke since 2016.||Detection of Unrecognized Tick-borne Febrile illness in the Upper Midwest and Northeast United States|
|2013||Trish Perl, MD At UT SW since 2016.||Clostridium difficile: Impact of colonization versus transmission on development of infection|
|2013||Cynthia Sears, MD||Does Disruption of Host Microbiota Modify Colorectal Cancer Risk?|
|2013||Christopher Heaney, PhD||Evolutionary dynamics of multidrug-resistant Staphylococcus aureus (MDRSA), a zoonotic pathogen of clinical significance, among industrial food animal production workers|